Home » Stocks » Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Stock Price: $0.980 USD -0.040 (-3.92%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
After-hours: $0.990 +0.010 (0.98%) Oct 20, 7:46 PM

Stock Price Chart

Key Info

Market Cap 80.08M
Revenue (ttm) 7.21M
Net Income (ttm) -115.13M
Shares Out 81.71M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $0.980
Previous Close $1.020
Change ($) -0.040
Change (%) -3.92%
Day's Open 1.010
Day's Range 0.921 - 1.030
Day's Volume 5,834,421
52-Week Range 0.920 - 9.780

More Stats

Market Cap 80.08M
Enterprise Value 25.20M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 81.71M
Float 80.25M
EPS (basic) -1.68
EPS (diluted) -1.70
FCF / Share -1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 34.72M
Short Ratio 4.08
Short % of Float 43.27%
Beta 1.83
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.10
PB Ratio 1.87
Revenue 7.21M
Operating Income -120.31M
Net Income -115.13M
Free Cash Flow -96.82M
Net Cash 54.88M
Net Cash / Share 0.67
Gross Margin -741.31%
Operating Margin -1,668.27%
Profit Margin -1,596.50%
FCF Margin -1,342.57%
ROA -82.52%
ROE -240.39%
ROIC 2,013.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 1
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(91.84% upside)
Current: $0.980
Target: 1.88
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth649.51%97.62%27.66%194.8%---
Gross Profit36.144.822.441.910.65--
Operating Income-77.10-56.75-32.56-19.99-8.85-2.65-0.56
Net Income-71.45-55.67-32.42-20.00-8.85-2.54-0.60
Shares Outstanding63.9057.0050.1841.1431.3520.166.96
Earnings Per Share-1.12-0.98-0.65-0.49-0.28-0.13-0.09
Operating Cash Flow-45.72-30.07-27.80-13.57-4.62-2.36-0.37
Capital Expenditures-2.74-2.30-0.71-0.35-0.11-0.06-
Free Cash Flow-48.46-32.37-28.50-13.92-4.74-2.43-0.37
Cash & Equivalents31.7541.7562.7015.1912.376.280.30
Total Debt9.450.390.330.
Net Cash / Debt22.3041.3562.3614.9212.216.13-0.34
Book Value6.1627.5257.788.928.995.86-1.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Corbus Pharmaceuticals Holdings, Inc.
Country United States
Employees 141
CEO Yuval Cohen

Stock Information

Ticker Symbol CRBP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CRBP


Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Company for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.